Inside the deal: As leaked details goosed its stock, Acceleron's CEO pumped Merck for more cash
As leaked details of its potential merger with Merck were splashed across the internet, Acceleron behind the scenes used newfound interest from investors and a last-minute Hail Mary from an unnamed suitor to ply the drug giant for an even more pricey buyout, according to a play-by-play of the deal in an SEC filing.
After weeks of negotiation, Merck late last month agreed to acquire Acceleron and its lead rare cardiovascular disease drug sotatercept for $11.5 billion, confirming days of leaked details on the companies’ negotiations.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 120,000+ biopharma pros reading Endpoints daily — and it's free.